
This trial evaluated the safety, pharmacokinetics, and pharmacodynamics of orforglipron (LY3502970), an oral, non-peptide glucagon-like peptide-1 receptor agonist (GLP-1RA), in patients with type 2 diabetes (T2D). It involved five different dosing regimens, and a total of 51 participants received orforglipron, while 17 received a placebo. Gastrointestinal-related adverse events were the most common, occurring early in treatment. By the end of the 12-week study, orforglipron demonstrated significant reductions in glycated hemoglobin (HbA1c) and body weight, with a safety profile similar to other GLP-1RAs. The findings suggest that orforglipron may serve as a safe and effective once-daily oral treatment for T2D, potentially offering an alternative to injectable GLP-1RAs or peptide oral formulations with fewer restrictions.
Like
Save
Share